Last updated: April 27, 2026
Nitrofurantoin (monohydrate/macrocrystals) is a mature, chemically defined antibacterial. Market access is typically driven by (1) API availability and (2) solid-dose formulation capacity (capsules/tablets), with many brands sourcing from multiple API producers and multiple contract manufacturers (CMOs).
Who supplies nitrofurantoin API (monohydrate and related grades)?
Global API supply clusters around a small set of established producers that sell nitrofurantoin in bulk to branded generics and intermediates for finished-dosage CMO work. Typical product lines include nitrofurantoin monohydrate and nitrofurantoin macrocrystals (often described in industry materials as a controlled release of a specific particle-size range).
Common supplier archetypes in this segment
- API manufacturers supplying nitrofurantoin monohydrate and related specifications
- Intermediate producers supplying downstream API purification steps
- Formulation-capable CMOs that buy API and convert into finished capsules/tablets in compliance-ready processes
Which finished-dose manufacturers are active for nitrofurantoin macrocrystals?
Finished-dose nitrofurantoin macrocrystals (and variants like macrocrystal capsules) is frequently produced by CMO networks for branded and generic labelers. In practice, labelers select partners based on:
- capsule/tablet line capability for nitrofurantoin macrocrystals
- validated granulation, filling, and moisture control
- ability to match reference dissolution and particle-size behavior
Because nitrofurantoin is widely genericized and has long product histories, supplier lists in public channels often map more cleanly to authorized distributors and contract manufacturing networks than to a single “exclusive” manufacturer.
Supplier pathways: how procurement typically works
For a buying team sourcing nitrofurantoin (monohydrate/macrocrystals), procurement usually follows one of these two routes:
-
Direct API purchase + internal or CMO formulation
- Buyer contracts for API (monohydrate or macrocrystal API-equivalent) from an API manufacturer
- Buyer or CMO performs blending, encapsulation, and packaging
- Buyer controls dissolution target and stability strategy
-
One-stop formulation outsourcing
- Buyer sources finished dose (capsules or tablets) from a formulation CMO
- CMO manages API sourcing, compliance batch records, and release testing
For most commercialization plans, route (2) is chosen when speed and regulatory execution dominate. Route (1) is chosen when the buyer needs control over the formulation and supply continuity.
What grades/specifications matter for nitrofurantoin monohydrate vs macrocrystals?
Nitrofurantoin “macrocrystals” is not a separate drug substance name in every jurisdiction; it is commonly a morphology/particle-size-controlled form used to achieve a different dissolution profile compared with smaller-particle nitrofurantoin powder.
Procurement spec categories to align
- Physical form: monohydrate form for the drug substance supply
- Particle size distribution (macrocrystal behavior)
- Assay and impurities: nitrofurantoin content and nitro-reduction/oxidation-related impurity profiles
- Moisture content and handling conditions
- Microbial limits and residual solvents (where applicable)
- Regulatory status: DMF/CEP/EDQM alignment depending on target markets
Who are the “practical” suppliers buyers use: distributors and API trading routes
Even when API is produced by a specific manufacturer, many buyers transact through regional distributors who handle:
- customs clearance and batch traceability
- COA management
- consolidated logistics for multi-API baskets
For procurement execution, buyers typically maintain a dual approach:
- qualify at least one direct API source or long-term supply agreement
- qualify at least one distributor for continuity and reduced lead-time risk
Supplier due-diligence checklist (for R&D and manufacturing readiness)
When selecting nitrofurantoin (monohydrate/macrocrystals) suppliers, the hard gate items are:
- Quality documentation: COA, batch traceability, impurity profiles
- Analytical method compatibility: ability to support dissolution matching and internal release testing
- Process robustness: moisture and particle-size control history
- Regulatory support: availability of DMF reference or equivalent dossier documents for targeted markets
- Supply continuity: lead times, allocation terms, and back-up supply options
- CMO capability mapping (if outsourcing finished dose): capsule/tabs lines, humidity control, in-process controls, stability protocol execution
How to structure sourcing for commercialization
A robust procurement model for nitrofurantoin typically includes:
- one primary API or formulation supplier
- one secondary supplier already qualified at the QA documentation level
- at least one CMO or fill-finish partner that can accept the same drug substance spec
This is how companies keep formulation and regulatory timelines stable in the face of API allocation or short-cycle market demand shifts.
Key Takeaways
- Nitrofurantoin macrocrystals is a controlled particle-size/morphology form that drives dissolution behavior and must be specified and qualified, not assumed.
- Sourcing is usually managed through either (1) direct API purchase plus formulation and packaging or (2) finished-dose CMO outsourcing where the CMO controls the API supply chain.
- Supplier selection should be anchored to documentation and spec alignment: particle-size profile, impurity profiles, moisture control, and regulatory dossier support.
FAQs
1) Is nitrofurantoin macrocrystals a different active ingredient than nitrofurantoin monohydrate?
It is the same active ingredient, but with a controlled physical form (commonly particle-size related) that changes dissolution behavior versus smaller particle material.
2) What is the most important specification for macrocrystal procurement?
Particle-size distribution or macrocrystal behavior that supports the intended dissolution profile, along with standard chemical and impurity specifications.
3) Do companies typically buy API directly or purchase finished doses?
Both models are used. API-direct is common for control of formulation and stability strategy. Finished-dose CMO is common when speed and regulatory execution matter most.
4) What QA artifacts should be required from a nitrofurantoin supplier?
Batch COA with assay and impurity profiles, traceability, and documentation supporting the physical form and handling (moisture) controls.
5) What supplier documentation enables regulatory submissions?
Drug master file (DMF) or equivalent dossier documentation that aligns with target markets, plus method/impurity data that supports bridging and release testing.
References
No sources were provided in the prompt, and this response does not include external citations.
